Exchange: NASDAQ·Updated 05:13 AM EDT
News
all
press releases
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
Stocktwits
More News
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight
BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.
Stocktwits
Why Is Tempus AI Stock Gaining Thursday?
Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B acquisition of Personalis.read more...
Benzinga
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.
Stocktwits
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.
Zacks
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?
TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.
Zacks
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside
TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.
Zacks
Why Is Tempus AI Stock Surging on Friday?
Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.read more...
Benzinga
Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?
HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.
Zacks
CellCarta Adds Tempus to CDx Commercialization Lab Network
CellCarta Adds Tempus to CDx Commercialization Lab Network CellCarta Adds Tempus to CDx Commercialization Lab Network PR Newswire MONTREAL, Aug. 6, 2026 Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.MONTREAL...
PR Newswire

Advertisement|Remove ads.